[HTML][HTML] Artificial intelligence to deep learning: machine intelligence approach for drug discovery
Drug designing and development is an important area of research for pharmaceutical
companies and chemical scientists. However, low efficacy, off-target delivery, time …
companies and chemical scientists. However, low efficacy, off-target delivery, time …
Multifaceted functions of RPS27a: An unconventional ribosomal protein
J Luo, H Zhao, L Chen, M Liu - Journal of Cellular Physiology, 2023 - Wiley Online Library
The ribosomal protein S27a (RPS27a) is cleaved from the fusion protein ubiquitin–RPS27a
(Ub–RPS27a). Generally, Ub and RPS27a are coexpressed as a fusion protein but function …
(Ub–RPS27a). Generally, Ub and RPS27a are coexpressed as a fusion protein but function …
Personalizing adjuvant therapy for patients with colorectal cancer
L Yang, J Yang, A Kleppe, HE Danielsen… - Nature Reviews Clinical …, 2024 - nature.com
The current standard-of-care adjuvant treatment for patients with colorectal cancer (CRC)
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …
comprises a fluoropyrimidine (5-fluorouracil or capecitabine) as a single agent or in …
[HTML][HTML] Epithelial-mesenchymal transition and MicroRNAs in colorectal cancer chemoresistance to FOLFOX
The FOLFOX scheme, based on the association of 5-fluorouracil and oxaliplatin, is the most
frequently indicated chemotherapy scheme for patients diagnosed with metastatic colorectal …
frequently indicated chemotherapy scheme for patients diagnosed with metastatic colorectal …
[HTML][HTML] Post-transcriptional regulation of colorectal cancer: a focus on RNA-binding proteins
JM García-Cárdenas, S Guerrero… - Frontiers in molecular …, 2019 - frontiersin.org
Colorectal cancer (CRC) is a major health problem with an estimated 1. 8 million new cases
worldwide. To date, most CRC studies have focused on DNA-related aberrations, leaving …
worldwide. To date, most CRC studies have focused on DNA-related aberrations, leaving …
[HTML][HTML] Colon cancer pharmacogenetics: A narrative review
ÁE Alfaro Alfaro, B Murillo Castillo, E Cordero García… - Pharmacy, 2022 - mdpi.com
Currently, metastatic colon cancer is treated with monotherapeutic regimens such as folinic
acid, fluorouracil, and oxaliplatin (FOLFOX), capecitabine and oxaliplatin (CapeOX), and …
acid, fluorouracil, and oxaliplatin (FOLFOX), capecitabine and oxaliplatin (CapeOX), and …
[HTML][HTML] OncoOmics approaches to reveal essential genes in breast cancer: a panoramic view from pathogenesis to precision medicine
Breast cancer (BC) is the leading cause of cancer-related death among women and the
most commonly diagnosed cancer worldwide. Although in recent years large-scale efforts …
most commonly diagnosed cancer worldwide. Although in recent years large-scale efforts …
[HTML][HTML] Prediction of breast cancer proteins involved in immunotherapy, metastasis, and RNA-binding using molecular descriptors and artificial neural networks
A López-Cortés, A Cabrera-Andrade… - Scientific reports, 2020 - nature.com
Breast cancer (BC) is a heterogeneous disease where genomic alterations, protein
expression deregulation, signaling pathway alterations, hormone disruption, ethnicity and …
expression deregulation, signaling pathway alterations, hormone disruption, ethnicity and …
[HTML][HTML] The close interaction between hypoxia-related proteins and metastasis in pancarcinomas
Many primary-tumor subregions exhibit low levels of molecular oxygen and restricted access
to nutrients due to poor vascularization in the tissue, phenomenon known as hypoxia …
to nutrients due to poor vascularization in the tissue, phenomenon known as hypoxia …
Multi-target drug discovery via ptml modeling: applications to the design of virtual dual inhibitors of cdk4 and her2
Background: Cyclin-dependent kinase 4 (CDK4) and the human epidermal growth factor
receptor 2 (HER2) are two of the most promising targets in oncology research. Thus, a series …
receptor 2 (HER2) are two of the most promising targets in oncology research. Thus, a series …